steer trial semaglutide Novo Nordisk's Study: Wegovy Cuts Cardiovascular Risk 57 % vs. Tirzepatide STEER_SCORE trial for the use

Tirzepatide primarily targets post-meal glucose through insulin secretion and gastric emptying

1 About Wegovy (semaglutide 2.4 mg) Wegovy (once-weekly subcutaneous semaglutide 2.4 mg) is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with a BMI of 30 kg/m 2 or greater (obesity), adults with a BMI of 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition, and paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) 8

Carnitines importance stems from its central role in transporting ALL fat to the site within each cell where it is burned

PMID: 84 MatoukCCMarsdenPA